Seastar Medical Holding CORP 8-K filings

SeaStar Medical Holding Corporation's Special Meeting of Stockholders was adjourned to March 28, 2025, due to the company not achieving a quorum.

SeaStar Medical receives an extension from Nasdaq until June 22, 2025, to meet the minimum market value of listed securities requirement of $35 million.

SeaStar Medical has entered into a securities purchase agreement for a $6 million registered direct offering with a single institutional investor.

SeaStar Medical received a public reprimand from Nasdaq for issuing shares without proper shareholder approval, though the company's stock listing remains unaffected.

SeaStar Medical provided an update on its commercial launch of QUELIMMUNE for pediatric acute kidney injury and progress in its adult acute kidney injury clinical trial.

SeaStar Medical Holding Corporation has received a delisting notification from Nasdaq after failing to regain compliance with the minimum market value requirement.

SeaStar Medical is facing a stockholder derivative lawsuit alleging false statements, fiduciary breaches, and internal control deficiencies, similar to a previously disclosed class action.

SeaStar Medical Holding Corporation's stockholders approved proposals to ratify share issuances, reduce authorized shares, and allow for meeting adjournment if needed.

SeaStar Medical announced its third quarter 2024 financial results, highlighted by the first commercial sales of its QUELIMMUNE device and progress in its clinical trials.

SeaStar Medical has reached a settlement with Nuwellis, resolving a dispute over a distribution agreement, with SeaStar agreeing to pay $900,000.

SeaStar Medical Holding Corporation has entered into an agreement with H.C. Wainwright & Co., LLC to sell up to $25 million of its common stock through an at-the-market offering.

SeaStar Medical announced its second quarter 2024 financial results, marking initial commercial sales of its QUELIMMUNE device and progress in its adult AKI clinical trial.

SeaStar Medical has successfully completed a $10 million registered direct offering and concurrent private placement to bolster its financial position.

SeaStar Medical Holding Corporation is facing a class action lawsuit alleging material misstatements and omissions regarding the company's business and operations, including disclosures related to FDA approvals.

SeaStar Medical has informed Nasdaq about a potential violation of listing rules related to the issuance of shares upon conversion of convertible notes and exercise of warrants.

SeaStar Medical has entered into an agreement to redeem all outstanding warrants held by an institutional investor for a total of $449,734.80, effectively settling related debt obligations.

SeaStar Medical received a Nasdaq notification for failing to meet the minimum market value of listed securities requirement, while successfully regaining compliance with the minimum bid price rule.

SeaStar Medical Holding Corporation redeemed and converted outstanding convertible notes with Investor D, eliminating this debt and issuing new shares.

SeaStar Medical has appointed three new members to its Board of Directors, including John Neuman, Jennifer A. Baird, and Bernadette N. Vincent, as the company transitions to a commercial-stage operation.

SeaStar Medical has implemented a 25-for-1 reverse stock split effective June 7, 2024, to increase its stock price and regain compliance with Nasdaq listing requirements.

SeaStar Medical Holding Corporation's stockholders approved the election of three Class II directors, an amendment to the equity incentive plan, the issuance of shares upon warrant exercise, and the ratification of the company's accounting firm at a special meeting on June 4, 2024.

SeaStar Medical announced its first quarter 2024 financial results, highlighting progress in clinical trials for its Selective Cytopheretic Device (SCD) and the upcoming launch of Quelimmune Pediatric.

SeaStar Medical Holding Corporation has amended its bylaws to reduce the quorum threshold for stockholder meetings and remove the 'Acting in Concert' definition.

SeaStar Medical announced its 2023 financial results, highlighted by the first FDA approval for its Quelimmune device for pediatric acute kidney injury and sepsis, and provided updates on clinical trials and corporate activities.

SeaStar Medical will restate financial statements for 2022 and interim 2023 periods due to accounting treatment of warrants and a prepaid forward purchase arrangement, but expects no material impact on cash or operations.

SeaStar Medical Holding Corporation announced it will restate its financial statements for 2022 and the first three quarters of 2023 due to misclassifications of warrants and prepaid forward purchase agreements.

SeaStar Medical will restate its financial statements for 2022 and interim 2023 periods due to accounting treatment of certain financial instruments, and will host a business update call on April 17th.

SeaStar Medical has received a temporary extension from Nasdaq until June 24, 2024, to regain compliance with the minimum bid price rule.

SeaStar Medical's Selective Cytopheretic Device (SCD) Pediatric has received FDA Humanitarian Device Exemption (HDE) approval for use in children with acute kidney injury (AKI) and sepsis.

SeaStar Medical Holding Corporation has mutually agreed to terminate its $100 million equity line of credit agreement with Tumim Stone Capital, effective immediately.